Korim Index · Monthly analysis · Updated
What should Healthcare & Life Sciences buyers pay for now: greater visibility in AI answers, tighter control of drug delivery, or clinical software that fits hospital workflows? For October, Korim’s commercial priority is the evidence connecting each purchase to an operational result. Sell accurate medical information, demonstrable production resilience and usable clinical data, rather than a broad promise of digital transformation. Each needs a different buying case.
Top opportunities this month
- Sell medical answer monitoring
Target pharmaceutical medical affairs leads and medical communications agency directors with a fixed-scope baseline audit followed by a monitoring subscription.
- Diligence packaging before paying a premium
Target pharmaceutical corporate development directors, manufacturing leaders and quality heads with a paid diligence package before an acquisition or supplier investment.
- Contract for a dementia recruitment workflow
Target NHS research directors and trial sponsor operations leads with a staged integration contract.
Korim's view
Focus on work with a named owner and a measurable acceptance test. Medical communications teams should sell information monitoring and correction. Pharmaceutical advisers should sell asset diligence tied to production dependencies. Clinical software businesses should sell governed integration with a defined adoption route. Assess value through resolved information errors, documented supply exposure and reduced manual work. Do not pay an acquisition premium merely because a business uses AI or has a hospital relationship.
What changed this month
AI visibility needs a medical accuracy test
A June survey of 7,500 respondents across 10 markets found that 56% had requested or would consider requesting a test, treatment or prescription based on information learned from AI. This is consumer evidence, not a measure of clinicians’ search behaviour. Answer engine optimisation technologies cover content citation, webpage crawlability and indexability, and visibility and sentiment measurement. The commercial distinction for medical communications is therefore important: being mentioned is a distribution outcome; presenting accurate, appropriately scoped medical information is the service worth testing.
Production control sharpens the packaging investment case
Research published in January describes leading pharmaceutical companies acquiring end-to-end production capabilities to hedge against bottlenecks. It also reports that strategic pharma deal value through 15 November 2025 rose 79% against the same period in 2024. That is historical deal context, not an October growth rate or packaging-specific valuation signal. August 2026 draft US guidance addresses quality evaluation of drug and biological-product container closure systems, including device constituent parts of combination products. It remains non-binding and not for implementation. Packaging diligence should examine technical dependencies, not assume regulatory change guarantees returns.
Linked records demonstrate utility, but adoption needs ownership
In England during 2023 and 2024, automated surveillance linking routine laboratory and hospital encounter records matched 71,556 of 73,807 locally identified bacteraemias (97.0%). Centrally generated metadata fields were as complete as or more complete than locally reported fields. This supports a concrete use case for linked records, rather than a general claim about clinical AI performance. Separate UK research identifies poorly defined NHS data-sharing mechanisms and partnership pathways, with successful pilots rarely having a clear route to system-wide adoption. Technical validation and a purchasing route must be developed together.
Where the opportunity lies
Sell medical answer monitoring
Target pharmaceutical medical affairs leads and medical communications agency directors with a fixed-scope baseline audit followed by a monitoring subscription. Deliver a repeatable question set, captured answers, citation checks, a clinically reviewed error register and correction recommendations for owned content. Separate patient-facing questions from professional enquiries so that results do not blur audiences. Price against coverage and review workload, not promised prescribing effects. The acceptance test should combine reproducible monitoring with documented resolution of material information gaps, rather than an aggregate visibility score alone.
Diligence packaging before paying a premium
Target pharmaceutical corporate development directors, manufacturing leaders and quality heads with a paid diligence package before an acquisition or supplier investment. Deliver a product-to-container dependency map, capacity and transfer assessment, quality evidence inventory and costed remediation plan. Separate evidence of current operating capability from gaps identified against proposed guidance. Assess value through the buyer’s documented exposure to production interruption and the work needed to qualify alternatives. Recommend an acquisition only when control provides a stronger economic answer than contractual supply protection or targeted capacity investment.
Contract for a dementia recruitment workflow
Target NHS research directors and trial sponsor operations leads with a staged integration contract. An international Alzheimer’s prevention trial recruiting 1,600 healthy adults aged 55 to 80 uses blood tests to identify likely participants, providing a specific workflow to investigate rather than proof of digital screening demand. Deliver a data dictionary, permissions matrix, eligibility review queue and referral audit trail. Tie progression to verified matching quality, staff time and completed referrals. Establish responsibility for clinical review and a route to wider purchasing before expanding the pilot.
What could weaken the case
- Consumer willingness does not establish clinician adoption or a monitoring budget. Reject the subscription case where buyers cannot identify material information problems or an accountable review owner.
- Broad pharma deal activity does not establish packaging returns. Test customer concentration, transferable capability and remediation costs before assigning a premium.
- Surveillance matching does not validate dementia diagnosis or recruitment performance. Stop expansion where data permissions, clinical review or a purchasing route remain unresolved.
What to watch next
- Medical communications briefs specifying answer accuracy, review ownership and recurring measurement.
- Packaging diligence requests linking quality evidence to named production dependencies, alongside changes to the draft guidance’s status.
- NHS research agreements naming data access responsibilities, referral measures and the decision-maker for wider adoption.
Research behind the analysis
EY’s survey of 7,500 respondents across 10 markets found that 56% had requested or would consider requesting a test, treatment or prescription based on information learned from AI.
EY ·Forrester identifies answer engine optimisation technologies as tools for creating content that answer engines mention and cite, improving webpage crawlability and indexability, and measuring visibility and sentiment across engines.
Forrester ·Leading pharmaceutical companies are acquiring end-to-end production capabilities to hedge against bottlenecks, while strategic pharma deal value through 15 November 2025 rose 79% compared with the same period in 2024.
Bain & Company ·The FDA’s August 2026 draft guidance sets out principles for evaluating the quality of drug and biological-product container closure systems, including those that are device constituent parts of combination products, but remains non-binding and not for implementation.
FDA ·BCG identifies poorly defined NHS data-sharing mechanisms and partnership pathways as barriers to innovation, with industry innovators struggling to find NHS entry points and successful pilots rarely having a clear route to system-wide adoption.
BCG ·In England in 2023, 2024, automated surveillance linking routinely collected laboratory and hospital encounter records matched 71,556 of 73,807 locally identified bacteraemias (97.0%), with centrally generated metadata fields as complete as or more complete than locally reported fields.
UK Health Security Agency ·Surrey and Borders Partnership NHS Foundation Trust joined an Alzheimer's prevention trial recruiting 1,600 healthy adults aged 55 to 80 internationally, with researchers using blood tests to identify those most likely to benefit from participation.
BBC News ·An OECD review of dementia policies across 29 countries found increasing emphasis on prevention and early diagnosis, but limited efforts to improve diagnostics.
OECD ·